Vericel Corporation (VCEL): Price and Financial Metrics

Vericel Corporation (VCEL): $38.31

-1.88 (-4.68%)

POWR Rating

Component Grades













Add VCEL to Watchlist
Sign Up

Industry: Biotech


of 476

in industry


  • VCEL scores best on the Quality dimension, with a Quality rank ahead of 69.26% of US stocks.
  • VCEL's strongest trending metric is Sentiment; it's been moving down over the last 52 weeks.
  • VCEL's current lowest rank is in the Sentiment metric (where it is better than 3.93% of US stocks).

VCEL Stock Summary

  • VCEL's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 2,898.91 -- higher than 98.57% of US-listed equities with positive expected earnings growth.
  • With a price/earnings ratio of 8,792.08, Vericel Corp P/E ratio is greater than that of about 99.93% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for Vericel Corp is higher than 92.71% of stocks in our set with a positive cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Vericel Corp are EVA, HQY, CHGG, LUV, and RDY.
  • Visit VCEL's SEC page to see the company's official filings. To visit the company's web site, go to

VCEL Valuation Summary

  • In comparison to the median Healthcare stock, VCEL's price/sales ratio is 47.14% higher, now standing at 16.7.
  • VCEL's EV/EBIT ratio has moved up 283.1 over the prior 243 months.
  • VCEL's EV/EBIT ratio has moved up 283.1 over the prior 243 months.

Below are key valuation metrics over time for VCEL.

Stock Date P/S P/B P/E EV/EBIT
VCEL 2021-08-31 16.7 16.7 288.3 275.6
VCEL 2021-08-30 17.1 17.2 296.3 283.3
VCEL 2021-08-27 17.1 17.2 295.9 283.0
VCEL 2021-08-26 16.2 16.2 280.1 267.8
VCEL 2021-08-25 16.5 16.6 286.1 273.6
VCEL 2021-08-24 16.2 16.3 280.5 268.2

VCEL Growth Metrics

  • The year over year cash and equivalents growth rate now stands at 27.68%.
  • Its 5 year revenue growth rate is now at 139.83%.
  • Its 5 year price growth rate is now at 283.05%.
Over the past 33 months, VCEL's revenue has gone up $62,965,000.

The table below shows VCEL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 153.822 29.826 0.214
2021-06-30 151.574 30.762 8.763
2021-03-31 132.069 22.972 4.28
2020-12-31 124.179 17.572 2.864
2020-09-30 118.34 9.385 0.145
2020-06-30 116.581 12.707 -0.003

VCEL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VCEL has a Quality Grade of C, ranking ahead of 72.89% of graded US stocks.
  • VCEL's asset turnover comes in at 0.761 -- ranking 35th of 682 Pharmaceutical Products stocks.
  • TCON, NMTR, and PTCT are the stocks whose asset turnover ratios are most correlated with VCEL.

The table below shows VCEL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.761 0.699 0.052
2021-03-31 0.732 0.685 0.031
2020-12-31 0.753 0.678 0.023
2020-09-30 0.779 0.671 0.001
2020-06-30 0.793 0.670 0.000
2020-03-31 0.866 0.683 -0.094

VCEL Price Target

For more insight on analysts targets of VCEL, see our VCEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $65.04 Average Broker Recommendation 1.29 (Strong Buy)

VCEL Stock Price Chart Interactive Chart >

Price chart for VCEL

VCEL Price/Volume Stats

Current price $38.31 52-week high $68.94
Prev. close $40.19 52-week low $24.31
Day low $37.37 Volume 272,000
Day high $40.32 Avg. volume 561,187
50-day MA $47.42 Dividend yield N/A
200-day MA $52.01 Market Cap 1.79B

Vericel Corporation (VCEL) Company Bio

Vericel Corporation focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company was founded in 1989 and is based in Cambridge, Massachusetts.

VCEL Latest News Stream

Event/Time News Detail
Loading, please wait...

VCEL Latest Social Stream

Loading social stream, please wait...

View Full VCEL Social Stream

Latest VCEL News From Around the Web

Below are the latest news stories about Vericel Corp that investors may wish to consider to help them evaluate VCEL as an investment opportunity.

Vericel Co. (NASDAQ:VCEL) Shares Bought by Amalgamated Bank

Amalgamated Bank raised its position in Vericel Co. (NASDAQ:VCEL) by 276.1% during the 2nd quarter, Holdings Channel reports. The firm owned 24,738 shares of the biotechnology companys stock after acquiring an additional 18,161 shares during the quarter. Amalgamated Banks holdings in Vericel were worth $1,299,000 at the end of the most recent reporting period. Other []

Transcript Daily | November 12, 2021

Vericel to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on November 18th, 2021

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on Thursday November 18 th , at 10:00a.m. Eastern Time.

Intrado Digital Media | November 11, 2021

Vericel (VCEL) Q3 2021 Earnings Call Transcript

Thank you, Eric and good morning, everyone. The spread of the Delta variant and the resulting disruptions to healthcare networks and patient behavior dynamics clearly impacted MACI revenue in the quarter.

Yahoo | November 10, 2021

Vericel (NASDAQ:VCEL) Shares Gap Down to $43.10

Vericel Co. (NASDAQ:VCEL)s share price gapped down before the market opened on Tuesday . The stock had previously closed at $43.10, but opened at $38.75. Vericel shares last traded at $42.20, with a volume of 3,483 shares. VCEL has been the topic of several recent analyst reports. SVB Leerink lowered their price objective on shares []

Dakota Financial News | November 9, 2021

Vericel Corporation (VCEL) Reports Q3 Loss, Misses Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -266.67% and -11.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2021

Read More 'VCEL' Stories Here

VCEL Price Returns

1-mo -16.75%
3-mo -29.28%
6-mo -30.92%
1-year 52.02%
3-year 117.92%
5-year 1,496.25%
YTD 24.06%
2020 77.47%
2019 0.00%
2018 219.27%
2017 81.67%
2016 16.28%

Continue Researching VCEL

Here are a few links from around the web to help you further your research on Vericel Corp's stock as an investment opportunity:

Vericel Corp (VCEL) Stock Price | Nasdaq
Vericel Corp (VCEL) Stock Quote, History and News - Yahoo Finance
Vericel Corp (VCEL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7829 seconds.